This forum is for questions about medical issues and research aspects of
Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new
Hepatitis Social/Living with Hepatitis forum
My husband also has HCV and this forum has been my world now for about 4 months. I can't help you on your question about gene therapy but I can provide some insight on Platelets.
Dr. Dieterich is Vice Chair and Chief Medical Officer Department of Medicine at The Mount Sinai Medical Center and an attending physician at New York University Tisch Hospital. He states the following:
I would not reduce dose personally if there were no sign of bleeding. There is a cytokine that can be used to raise platelet counts called Neumega. It is IL-11 and does work reasonably well. You should ask your MD about it. The lower the platelets the more your husband needs the interferon!
My husband is on both Neupogen and Procit, he has not had an easy time with the med's. We (I) am very assertive in doing research and making sure that the Dr's listen to me. Everyday I hold my breath and hope he won't develop some other problem that could potentially take him off his meds. It's one day at a time...
Good luck, my thoughts are with you.
Debbe
I guess the problem with the platelet booster we are facing is the insurance company. The drug they want him to take has not been fda approved for hcv patients. Funny though, they use the same drug for chemo patients for the exact same thing. Go figure.
I hope things go well for you and your husband. It is very difficult to seem them going through something this tough.
All we can do is stand by them and make sure they know we are there for them.
prayer and thoughts to you both!!
sharon
Hope this helps,
Good luck to you and have a wonderful holiday..
Jodi
I suppose it is at the Doc's discretion.(guessing)!!
thank you!! Have a wonderful holiday
sharon
Neumega is FDA approved since 11-1997. It is at the Dr's discretion which can be very frustrating. It took us 4 different Doctors before we found one that listens to us and doesn't automatically reduce meds at the first sign of trouble. Nuemega has a website, click <A href="http://nuemega.com">Here</A>.
Keep us posted,
Debbe
This web site is a God send.
Thanks to everyone who posted to my inquiry.
sharon
Don't take an automatic decline from the insurance company on face value. They HOPE you will go away quietly. Usually, if you appeal (include a letter from the doctor or medical references if you can get 'em) they buckle.
If they deny, appeal! If they deny again, appeal again! It helps get your frustrations out, if nothing else, knowing you are bothering them.
I had to go so far as to get a letter from an attorney once (appealing an unrelated issue)--stating how if my health suffered from their denying payment for care, I would be forced to look into seeking financial recompense, etc etc. They paid so fast after that my head spun.
Procrit (epogen) is used to boost red blood cells and neupogen is used to boost white blood cell counts.
regards,
BobK
http://health.groups.yahoo.com/group/happyheppers/message/2754
That is all I can say for now cuz my back is killing me!!! I over did and now it hurts! So see ya all later, hugs OHC
Couch Potato, I started worrying about his platelets when they told us his count was down to 100 (this was two weeks ago). I can't imagine them being lower. He is really pale and gets dizzy when trying to do anything strenuous. I hope your hubby is doing better than mine.
BobK, there is a treatment called Neumega that helps with platelet loss. Better Angels posted a web site for this treatment in an earlier posting.
Hope all is well!!
sharon
god with all!!!
sharon
p.s. sorry for the outburst. Need some sort of release!
Good luck!
TX partner from CT
There is a very good reason why you and others have not heard of patients being treated with neumega for reduced platlet levels during treatment. Dangerous side effects (from my reading)of neumega include plasma volume expansion which would significantly reduce hemoglobin and WBC counts. The edema associated with using this drug could be very dangerous for someone with advanced liver disease or hypertension. Neumega also has been shown to increase rates of fibrosis (particularly pulminary)in animal models. There is very little data for long-term use in humans.
This drug is by no means a magic bullet to combat low platelets and I would be very suprised if you could find a doctor willing to go out on a limb and prescribe this drug.
I would, on the other hand, be very interested in what your doctors say about the potential use of this drug and if they would be willing to prescribe.
regards,
BobK
Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis.
Ghalib R, Levine C, Hassan M, McClelland T, Goss J, Stribling R, Seu P, Patt YZ.
Transplant Office at Methodist Hospital of Dallas, Houston, USA. ***@****
To elucidate the hematopoietic activity of recombinant human interleukin-11 (rhIL-11, [Neumega, Cambridge, MA]) in patients with cirrhosis and thrombocytopenia, we administered rhIL-11 at 50 microg/kg/d subcutaneously to 10 patients for 10 days with a 30-day follow-up period. All treated patients (n = 9) experienced a gradual, yet significant increase in their platelet count above the baseline value (P < or =.01) reaching the peak value (median, 93,000/microL; range, 60,000-206,000/microL) at a median of 13 days (range, 6-23 days). Eight patients (89%) had a significant increase of > or =50% over the baseline value (P <.05). Moreover, further increases to > or =60,000/microL, > or =80,000/microL, and > or =100,000/microL were observed in 100%, 78%, and 33% of the patients, respectively. A subsequent decline in platelet count was observed at a median of 19 days (range, 7-26 days) after the occurrence of peak concentration. A significant increase in neutrophil count was also demonstrated starting on the third day of treatment (P < or =.01). Concurrent with an increase in the serum level of fibrinogen, transaminase levels declined significantly during treatment period, while bilirubin levels continued to drop for up to 20 days after the initiation of treatment (P <.05). The most frequent effects were due to plasma volume expansion, including conjunctival redness and edema. In conclusion, rhIL-11 can improve platelet counts in patients with early cirrhosis and these patients could benefit from rhIL-11 treatment. However, given the high frequency of regimen-related toxicity, the use of rhIL-11 in patients with cirrhosis should be administered with caution.